Aspen Aerogels (NYSE:ASPN – Get Free Report) issued an update on its third quarter 2026 earnings guidance on Thursday. The company provided EPS guidance of -0.110–0.070 for the period, compared to the consensus EPS estimate of -0.130. The company issued revenue guidance of $65.0 million-$80.0 million, compared to the consensus revenue estimate of $56.6 million.
Wall Street Analysts Forecast Growth
A number of brokerages have weighed in on ASPN. Wall Street Zen upgraded Aspen Aerogels from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Roth Capital reissued a “buy” rating and issued a $5.75 price target on shares of Aspen Aerogels in a research note on Friday, May 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Aspen Aerogels in a report on Wednesday, June 24th. Finally, Barclays raised their price objective on shares of Aspen Aerogels from $3.00 to $4.00 and gave the stock an “underweight” rating in a research report on Monday, May 11th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Aspen Aerogels presently has a consensus rating of “Hold” and a consensus target price of $5.19.
Check Out Our Latest Stock Report on ASPN
Aspen Aerogels Price Performance
Aspen Aerogels (NYSE:ASPN – Get Free Report) last issued its earnings results on Thursday, August 6th. The construction company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.01. Aspen Aerogels had a negative return on equity of 22.16% and a negative net margin of 48.64%.Aspen Aerogels has set its Q3 2026 guidance at -0.110–0.070 EPS. Equities research analysts anticipate that Aspen Aerogels will post -0.8 earnings per share for the current fiscal year.
Institutional Trading of Aspen Aerogels
Several hedge funds have recently bought and sold shares of the business. WINTON GROUP Ltd bought a new position in shares of Aspen Aerogels in the fourth quarter valued at $40,000. StoneX Group Inc. acquired a new stake in shares of Aspen Aerogels in the 4th quarter worth about $41,000. Acadian Asset Management LLC bought a new position in Aspen Aerogels in the 1st quarter valued at about $43,000. Tower Research Capital LLC TRC boosted its stake in Aspen Aerogels by 184.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,235 shares of the construction company’s stock valued at $43,000 after purchasing an additional 4,693 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC bought a new stake in Aspen Aerogels during the 4th quarter worth approximately $58,000. Institutional investors and hedge funds own 97.64% of the company’s stock.
Aspen Aerogels Company Profile
Aspen Aerogels, Inc, headquartered in Northborough, Massachusetts, develops and manufactures high-performance aerogel insulation materials and custom engineered solutions. Founded in 2001 as a spin-out from Department of Energy research, the company pursued an initial public offering on the NYSE in 2014 under the ticker ASPN. Aspen Aerogels combines proprietary aerogel formulations with advanced manufacturing processes to deliver products known for their low thermal conductivity, lightweight construction and robust mechanical properties.
The company’s product portfolio spans blanket insulation, boards, and custom shapes built around several proprietary brands, including Pyrogel, Cryogel and Spaceloft.
Featured Stories
- Five stocks we like better than Aspen Aerogels
- Why Analysts Are Bullish on a Stock That’s Down 20%
- SpaceX: Love the Company, But the Stock Is a Harder Call
- Ulta’s Growth Is Real, But So Are the Risks
- BWX Technologies Is Turning the AI Power Problem Into a Nuclear Growth Story
Receive News & Ratings for Aspen Aerogels Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aspen Aerogels and related companies with MarketBeat.com's FREE daily email newsletter.
